Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Global Pharmaceutical & Biotechnology Outlook 2014: India Pharma

Enquire | Email | Print

Click Here!!! and Get this report in a Combo Package with 20% OFF!!!
Published Date: Jan, 2014
Format: PDF
No of Pages: 66
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Indian companies are taking center stage in Complex Generics at US and EU markets. In Bio-similars, Indian companies will have perhaps the largest basket aimed at Emerging Countries in 2014-16 and later for Developed countries. Though few but is the beginning of NCE/mAb development by Indian companies is a sign of Indian Generics moving up in the chain. The uncertainty of clinical and regulatory pathways in the US helps Asian biopharma and biotech companies to be in forefront in developing and marketing biosimilars. Biopharma/ biotech companies in India, S. Korea, China may have significant advantages of low-cost manufacturing, colossal markets, and healthy government support over potential peers from other regions. The cost barriers in the biosimilar market lead regulated marketed giants to tie up with Asian companies to gain access to these advantages and hedging their bets through a joint-venture strategy. Though reimbursement remains a concern as no countries provide full reimbursement – patient pay total cost out-of-pocket in India; with well defined regulatory pathways, we believe Indian biopharma companies keep leveraging their strength of low cost manufacturing along with skilled workforce which would support them to gain global recognition.

Factories at India continue to have lion’s share of US Generics market, despite a couple of plants at India facing scrutiny from US FDA. India has 526 USFDA units in which 403 intimations of violation (Form 483) of its manufacturing norms to Indian plants in the period from 2011 to Nov 2013. It is to be noted that one fourth of FDA inspection outside the US conducted in India. But Indian plants have received very less Import alerts/Warning letters by FDA which indicates strong quality consciousness of Indian Drug Manufacturers. Only 21 warning letters have been issued to Indian companies which is far less than other Ex-US countries (Mexico: 74%; Canada and British: 30% - Import alert).

With a robust outlook, companies continue to invest in sales force to target more doctors and more focus per brand. The implementation of quality norms with vigor has helped companies with better quality perception to charge high prices. Every company has invested in increasing the sales force to capture the market that has consolidated at the tail end. With tiny companies getting out of business importance of branding has increased drastically. Thus, all companies are trying to increase focus per brand. Policy makers in India to start the process of strict audit of marketing practices followed by pharma companies in India.Our outlook 2014 on India Pharma covers overall business and market growth for Indian companies, ParaIV filing, NCE pipeline and biosimilar and NDDS evelopment.

Key Topics Covered


1. Uniform Code on Sales and Marketing Practices in India
2. Issuance of warning letters to Indian facilities by USFDA: not a concern
3. Biosimilar perspective for Indian market
4. New drug discovery development in India
5. Biocon: Sits comfortable with its near and long term contributory products
6. Cadila Healthcare: NCE, Transdermal, Biosimilars and Complex generics launches thru 2016 –Eventful time ahead
7. Cipla: Major change in business model
8. Dr. Reddy’s Lab: Focus on Complex formulations and Biogenerics to intensify
9. Glenmark: US business, NCE and ParaIV will show significant growth
10. IPCA: Fine chemicals to formulation –Global leadership in select products
11. Lupin: US and Japan Business –Key for long term growth
12. Natco: Leveraging chemistry, formulation and IP strength –For Us and India Markets
13. Panacea Biotec: Financial trouble mounting, Acceptance of WHO prequalification and formulation business will revive the company
14. Shasun: On path to become fully integrated Pharma company
15. Shilpa Medicare: A leader in Oncology API, Expanding into Non-Onco, peptides and complex formulations
16. Sun Pharma: Strong Management Team - Absolute and Comparative Advantage

UNIFORM CODE ON SALES AND MARKETING PRACTICES IN INDIA: THE GROUND REALITY & THE IMPLICATIONS
Nothing Much Has Changed on the Ground Following the Issue of the Guidelines
-More Sophisticated Ways of Bribing Invented
-Different Companies Respond Differently in ‘Tackling’ the Guidelines
-Gifting Policy Changed
-Gifting Policy Changed

If Enforced Effectively – Uniform Codes Can Bring Signicant Changes on the Ground ‘Lack of Will’ and ‘Cut-Throat Competition’ are Bottlenecks in Implementing Ethical Practices

Drug Sampling Policies– Most Improved

‘Uniform Codes’ Were Not Relayed Properly to the Field Force Strong Enforcement of Guidelines May Hamper Revenues In Beginning, But Will Balanced Out In Long Run:

Doctors Become More Cautious In Dealing With Pharma Companies Following MCI And DOP Guidelines, Yet A Mutual Understating With Pharma Cos ‘Matures’ and Finds Ways To ‘Reciprocate’ Business:

Table 1: Domestic Sales As Percent Of Total Sales
Table 2: Alleged Nexus Among Doctors & Pharma Cos: Complain Vs. Action Trend
Table 3: Uniform Code For Marketing Practices – Deliberations Vs. Ground Reality
Table 4: Various Promotional Ways To Incur As Expenses By Pharma Companies

Other Notable Developments in Indian Pharma
ISSUANCE OF WARNING LETTERS TO INDIAN FACILITIES BY USFDA: NOT A CONCERN

Table 5: India Pharma: Fda Warning Letter Review 2010-2013

BIOSIMILAR PERSPECTIVE FOR INDIAN MARKET
Table 6: Approved Biosimilars In India
Table 7: Select Biosimilars Collaborations Till Date

Indian ‘Similar Biologics’ Guideline: Overview

DRUG DISCOVERY DEVELOPMENT IN INDIA
Table 8: NCE-MAB PIPELINE INDIAN COMPANIES
SUN PHARMA - Strong Management Team – Absolute and Comparative Advantage
Key Thesis

Domestic market – balanced portfolio, sustainable base
Table 1: Chronic Disease Focused Portfolio Leadership in Domestic Oncology Market is
Likely to be Maintained Overseas Market Business – Solid Fundamentals
Promise Future Growth
Table 2: Year Wise Approvals In The Us Derma – A protable Segment with High entry
barrier
Table 3: Therapy Wise Approvals In The Us A Decent Base in Europe Beyond Generics -
Investing in Innovation
• Improving Generics
• True Innovation

Annexure 1: History Of Creating Value Through Executing Value Assets

CIPLA: Major Change in Business Model
Key Thesis

Changing Leaderships, Changing Business Philosophies: Only Time will Unfold the Outcome Acquisition of Medpro – A Signal Indicating Change in the Global Business Strategy Domestic market Business
Table 1: Respiratory CoverageSolid Base to Enter ‘Front-End’ Marketing In Overseas Markets
• Capabilities in the Respiratory Area
Table 2: Strong Manufacturing To Cater To Global Markets
Table 3:Wide Technology Platform Base Initiatives to Bring Value to the Society Continue
• Accelerated Efforts in HIV/AIDS Field
• Cancer Palliative Care & Training Center
• alliance with ‘Drugs for Neglected Diseases initiative

Annexure 1: Cipla Business Summary
DR REDDY’S LAB - Focus on Complex Formulation and Biogenerics to Intensify
Key Thesis

Products continue to contribute US business:
Products expected to drive growth in future:
Russia/CIS – Momentum Continues
Table 1: Leadership Products In Russia
Table 2: Growth Of Otc Sales In RussiaDomestic Formulations
Table 3: Growth Of Otc Sales In Russia

Annexure 1: Indian Inc- Dependence On Domestic Sales
IPCA Laboratories- Fine Chemicals to Formulation – Global Leadership in Select Products
Key Thesis
Research and Development
Domestic Formulations – Steady Growth
Anti Malarial Tender Business – Strong Outlook
Export – Formulation
WHO Prequalied Anti Malarial Producers

IPCA Laboratories- Fine Chemicals to Formulation – Global Leadership in Select Products
Key Thesis
Research and Development
Domestic Formulations – Steady Growth
Anti Malarial Tender Business – Strong Outlook
Export – Formulation
WHO Prequalied Anti Malarial Producers

Lupin Pharma - US and Japan Generic Business – Key for Long Term Growth
Key Thesis
Japan – Supplies from India to Improve Margins
Domestic – Disappointed
Branded business
Upcoming FTF Opportunities
Generic Business – Key Highlights
R&D Investments

Natco Pharma - Leveraging Chemistry, Formulation and IP Strengths – For US and India
markets
Key Thesis
Domestic Formulations – Oncology Focused Portfolio
API Exports
NCE Pipeline
Key Oncology drugs in Domestic Market To Add Value In coming Years
Export Formulation

Shasun Chemicals & Drugs Limited - On Path to become a Fully integrated Pharma
Company
Key Thesis
CRAMS business
Biotechnology and Nanotechnology
New facility in Development
Shasun Pharma Solutions Limited, UK

Shilpa Medicare - A Leader in Oncology API, Expanding into Non-Onco, Peptides and Complex Formulations
Key Thesis
Oncology API in Pipeline
Anti-retro viral, low margin business, competitive but sustains the cash ow
Non-Oncology APIs Under Development
Manufacturing Facilities
Research and Development
Acquisitions so far

Biocon – Biocon Sits Comfortable with its Near & Long Term Contributory Products
Key Thesis
Near term growth drivers
Long term growth drivers
Branded Formulations and Contract Research Services Growing Robustly
World's rst trastuzumab biosimilar (Canmab) from BIOS
R&D Partnership Update in Fy13
Review of NCE Pipeline from BIOS
Evertor (Everolimus)-No competition yet in India
Insulin Business Update

Cadila Healthcare Ltd: One NCE launched and few in waiting, Bio-similars,Transdermal and Complex Generics launches thru 2016– Eventful Time Ahead
Key Thesis
Long term Outlook visible
US business expected to grow
Additional new products will revive JV business prospects in the near term
US approval of Two Transdermal products
Complex generics other than the transdermal opportunities
Mesalamine Franchise –– A low competition opportunity for CDH
Novel dual PPAR agonist: Saroglitazar outlook
Notable NCE/NBE Pipeline review including Biosimilar

Glenmark: Complex Generics and NDDS (Transdermal) will Show Signicant Growth
Key Thesis
Business Segments Review
Indian Market Position and US and RoW Business review
Glenmark Research Capabilities
R&D Pipeline Update

Panacea Biotec Ltd: Financial Trouble mounting, Acceptance of WHO pre-qualication and Formulation Business will revive the company
Key Thesis
Panacea has the ability to revive
Business segments review: India and International Business
Strategic Alliances
Research Capabilities
Formulation Platform Technologies Developed
Manufacturing Facilities- Regulatory Approval
WHO and UNICEF Vaccine Business Update 

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 364876, price: INR 151309, MP Advisors

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online